The EVIDENCE 360: RWE, Pricing & Reimbursement Summit USA is a premier event dedicated to exploring the evolving role of Real-World Evidence (RWE) in shaping healthcare policies, drug pricing strategies, and reimbursement frameworks in the United States.
Set to take place on June 26-27, 2025, in Philadelphia, USA, this highly anticipated Real-World Evidence Conference in the USA will bring together industry leaders, regulatory experts, payers, and data scientists to discuss cutting-edge advancements in RWE analytics, big data to revolutionize RWE analysis, and its increasing impact on market access.
As the healthcare landscape shifts towards data-driven decision-making, this real-world evidence conference in the USA will focus on integrating RWE into regulatory submissions, demonstrating value-based pricing, and overcoming challenges in fragmented reimbursement policies.
By leveraging innovative technologies such as artificial intelligence (AI) and machine learning, the summit aims to equip professionals with the latest insights to optimize patient access and improve healthcare outcomes.
Key Topics
The summit will address several critical areas, including:
• Bridging Clinical Trials and Real-World Outcomes: Strategies to align clinical trial data with real-world outcomes to enhance healthcare access.
• Leveraging Advanced Analytics: Utilizing artificial intelligence, machine learning, and big data to generate actionable insights from real-world datasets.
• Patient-Centric Data: Incorporating Patient-Reported Outcomes (PROs) to optimize access strategies and promote patient-centered care.
• Navigating U.S. Reimbursement Policies: Addressing the complexities of fragmented reimbursement policies within the United States.
• Health Technology Assessments (HTAs): Exploring differences between U.S. HTA practices and global approaches to align pricing and reimbursement strategies with evolving healthcare policies.
Why Attend?
Attendees will gain valuable insights into:
• The latest RWE trends and their influence on pricing and reimbursement strategies in the USA.
• Networking opportunities with key industry leaders and regulators shaping the future of healthcare policy and market access.
• The role of RWE in regulatory decision-making and its impact on health technology assessments.
• The integration of AI and digital health in driving more efficient and effective reimbursement decisions.
• Collaborative approaches to overcoming challenges in integrating RWE and enhancing patient outcomes through data-driven decisions.
The EVIDENCE 360: RWE, Pricing & Reimbursement Summit USA is designed for a diverse group of professionals in the healthcare and pharmaceutical industries. This includes executives, decision-makers, and researchers from pharmaceutical and biotech companies focused on drug development, market access, and pricing strategies. The summit also targets representatives from healthcare authorities, regulatory bodies, and health technology assessment agencies across the USA, offering them a platform to collaborate and discuss RWE integration.
Researchers utilizing RWE to evaluate treatment outcomes, enhance healthcare models, and support regulatory submissions will find valuable insights. Additionally, advisors and payers involved in guiding pricing strategies, reimbursement processes, and RWE implementation, as well as investors interested in funding innovation in healthcare, particularly in RWE and value-based pricing models, will benefit from the summit's focused discussions and networking opportunities.
For more information and to register for the summit, visit https://veridonglobal.com/events/evidence-360-rwe-pricing-reimbursement-summit-usa/evidance-360-usa-registration/.
Comments
0 comment